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1 Introduction
A typical novel drug takes over 10 years and over
$1Billion from discovery to market (PhRMA, 2013).
The current pharmaceutical business model is being
questioned due to declining R&D productivity as
measured by approved drugs over R&D investments
(Cockburn, 2007; Scannell et al., 2012). One key met-
ric of productivity is cycle time of the R&D process.
Reducing the time to market has numerous busi-
ness benefits, such as longer exclusivity and reduced
costs (Mestre-Ferrandiz et al., 2012).
Operational Excellence (OpEx) methodologies have
long been used for productivity improvement (Ber-
tels, 2003). In the past few decades, a number of
new approaches emerged. The Six Sigma method-
ology, introduced by Motorola in 1980’s, empha-
sizes the use of statistical tools to understand and
reduce variation and improve quality. The Lean
methodology, popularized by the success of the
Toyota Production System, is widely used to elim-
inate waste and reduce cycle time for manufactur-
ing and product development processes. Many
organizations have combined these new method-
ologies with traditional quality improvement tools
in their implementation of Operational Excellence.
One common form of implementation is DMAIC,
which is the acronym for Define, Measure, Analyze,
Improve, and Control, a five-phase process improve-
ment approach originated from General Electric.
As illustrated in Figure 1, DMAIC is one form of the
Plan-Do-Check-Act (PDCA) cycle advocated by W.
Edwards Deming for scientific problem-solving and
continuous improvement (Deming, 1986).
Since the 1990’s, Operational Excellence method-
ologies have also been implemented to a varying
degree in pharmaceutical manufacturing to reduce
cycle time, improve quality, and control costs. In the
past few years, as improving R&D productivity
became an imperative, Operational Excellence was
introduced to many pharmaceutical R&D organi-
zations, ranging from DMAIC training of a small
group of individuals to divisional deployment of a
suite of OpEx methodologies. Management and
OpEx practitioners believed that the same disci-
plined improvement approach applies to the phar-
maceutical R&D process (from discovery of a drug
target to application for regulatory approval) as
well as manufacturing.   
While the OpEx methodologies worked well in a
project within one or two functional areas, practi-
tioners quickly realized they faced new challenges
when applying them to improve the core process
(Johnstone et al., 2011; Barnhart, 2013). For exam-
ple, engaging a local team in a Kaizen event to
improve their own process is effective. But when
the outcome is less defined and the processes inter-
twined among many organizations and geograph-
ical locations, a myriad of issues, from defining the
right metric to gaining the right sponsorship,
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emerge. As a result, many OpEx efforts have made
limited impact in R&D. Some practitioners were
quick to blame OpEx maturity and organizational
culture as the causes. But they are not unique to
pharmaceutical R&D and cannot explain all the
challenges. To understand these challenges, we
must first examine long-held beliefs and practices
taken for granted in manufacturing and service
environments, and ask: 
What is fundamentally different when striving
for productivity improvement in R&D as com-
pared to manufacturing or services?
What aspects of Operational Excellence are valid
and relevant for pharmaceutical R&D? What is
missing in the traditional approach? 
The intent of this article is not to cover the full spec-
trum of the challenges facing OpEx practitioners
and R&D business leaders. Instead, it focuses on
one key question:What is the role of process
improvement in transforming pharmaceutical R&D? 
In this article, to help readers appreciate the spe-
cific challenges, we first present a hypothetical case
that is based on our real-life observations of imple-
menting OpEx in many pharmaceutical R&D organ-
izations. It is used to illustrate one aspect of R&D
productivity improvement: cycle time reduction.
We then link the challenges to the critical differ-
ences between pharmaceutical R&D and manu-
facturing or services. We believe that the under-
standing of these differences is fundamental to
developing new perspectives and applying the right
methodologies in pharmaceutical R&D. Finally, by
considering the organizational reality in pharma-
ceutical R&D and applying the above understand-
ing, we propose a practical approach to reduce cycle
time and develop organization’s capability of con-
tinuous improvement.
2 The Challenge: A Cycle Time Reduction
Example
To illustrate the challenge in applying the tra-
ditional process improvement methodologies in
pharmaceutical R&D, consider the following sce-
nario.
In a global pharmaceutical company, a number
of R&D programs were facing competition from
multiple industry leaders, in some cases several
months to a year behind the leading competitor.
Based on external benchmarking, the executives
estimated that their company’s overall R&D cycle
time was about the same as or slightly longer than
the competitors. Therefore, it was imperative to
reduce the cycle times in the process wherever pos-
sible. A cycle time reduction project was chartered
to identify opportunities to streamline a sub-process
that had the worst performance.  The team was
led by a respected functional leader and coached
by an Operational Excellence veteran experienced
in improving both manufacturing and transaction-
al processes in other industries, and followed the
popular DMAIC framework. 
As a high-priority project, the team received
strong sponsorship from top management and
dedicated resources, both of which were uncom-
mon in the early stage of OpEx deployment. As a
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Figure 1 DMAIC and PDCA cycle.
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result, the Define phase went smoothly, and the
sponsors approved the project with a goal of reduc-
ing the average cycle time of a sub-process in Phase
II clinical development by 3 months. 
As soon as the team entered the Measure phase,
however, they encountered major obstacles: 
The process was poorly defined and document-
ed in various formats. The process flow varied
for each program because teams developed
their own way of performing common tasks.
No standardization was attempted.
Each program required some unique decision
points, branches, loops, and steps in the process.
No single process map could adequately describe
the current state.
With regards to cycle time, there was no oper-
ational definition or systematic measurement.
The data available was incomplete and incon-
sistent. 
The process was obviously not consistent, out-
liers common, and the measurement system not
reliable. If the baseline was undefined, what should
be the SMART (Specific, Measureable, Achievable,
Relevant, and Time-bound) goal statement at the
end of Measure? Should the project goal be 1) reduc-
ing the variation to have a better defined baseline
or 2) reducing the average cycle time as originally
chartered? Could the team achieve both objectives?
In Analyze, the cross-functional team worked
to identify the root causes of the long cycle time
and variation. Some common potential causes were
identified based on limited information of previ-
ous programs, including
Resource constraints (both internal and exter-
nal)
Technology/IT limitations (multiple conflicting
legacy systems)
Regulatory requirements (unclear or changing)
Product-specific requirements (translated into
unique tasks and deliverables)
Program priority (due to commercial/business
reasons)
Unexpected internal/external events (leading
to change in resources and course of action)
Most of such factors were categorical and attrib-
ute variables that were rarely operationally defined
and hard to quantify. Given the poor data available
for the few dozen programs, statistical analyses
typically required in Analyze were not possible. For
each program, a different set of factors seemed to
contribute to cycle time. There was hardly any Pare-
to effect or consensus on the critical few drivers.
What could the team do to verify the relative impact
of the factors and prioritize them for improvement?
Entering the Improve phase without a clear
focus on a few critical factors, the team brain-
stormed and developed an assortment of solutions
to address various causes. Eliminating various types
of waste led to a number of proposed changes.
Implementing automation to replace manual work
was a popular high-impact solution but required
capital investment and long-term planning. A final
recommendation was to identify best practices and
incorporate them into a global process as the future
state. Process maps, responsibility matrices, guid-
ance documents and templates were proposed to
guide the functions involved. During the imple-
mentation, a practical question then arose: to what
extent should we standardize or prescribe the solu-
tion without being seen as over-controlling or
bureaucratic? In an organization where the term
“process” was often viewed as a rigid structure that
stifled innovation and individual creativity, how
can the process be efficient, consistent, but also
flexible and enabling? The team knew that own-
ership and change management would be a big
issue in the Control phase.
The improvement project did not end with
implementation, even with sustained ownership
of the solutions. Despite visible process changes,
new roles and responsibilities, training of staff, and
a wide array of tools and templates, senior man-
agement’s question remained: “How can we be
sure that the new process is better, and by how
much? Can you assure us we will beat the compe-
tition?” Given the numerous changes happening
outside the project and many factors (from known
and controllable to unknown and uncontrollable)
that could influence the cycle time, the team saw
no single factor that could be a useful leading indi-
cator. Since it would take at least two years to have
one project go through the new process and many
more years to establish a new baseline, the team
was struggling to provide a convincing answer. In
the meantime, R&D program managers asked:
“How much could the new process improve MY
program’s cycle time?” Improvement in the aver-
age did not matter to them because each program
was so unique. Without a clear path forward, sen-
ior leadership reluctantly declared project success
so they could dissolve the team to free up resources,
but promised to “study the issue further.”
As the example shows, even a well prepared
OpEx team with strong leadership support faces
serious challenges when it comes to tackling process
improvements in an R&D environment. In reality,
the situation is often worse because most R&D
organizations exhibit a low level of OpEx maturi-
ty: poorly defined problems, lack of sponsorship,
project variability, and inexperienced teams. But
Journal of Business Chemistry 2014, 11 (1) © 2014 Institute of Business Administration 35
Improving R&D productivity requires a balanced approach
what is really unique about improving pharmaceu-
tical R&D processes? How should OpEx profession-
als approach it?  
3 Challenging assumptions: Pharmaceu-
tical R&D is different
To create a right mindset when approaching
the R&D process improvement challenge, it is help-
ful to revisit two unquestioned assumptions we
carry over from improving manufacturing or serv-
ices. 
Assumption 1: Variation is always undesirable.
This is not the case in R&D. The output of the phar-
maceutical R&D process is a new medicine, whose
ideal characteristics are often defined by the Tar-
get Product Profile. The path to achieve that goal
is much less defined at the beginning. The process
involves numerous decisions along the way, e.g.
choices among multiple biological pathways, mech-
anisms, or formulations. The decision to investi-
gate or pursue one way or the other depends on
the experience and human judgment of the knowl-
edge workers.  Some observed variability simply
reflects the freedom given to the teams to design
their own work and to innovate. Additional varia-
tion among projects is due to scientific or business
reasons.  For example, the therapeutic area influ-
ences the design and duration of a clinical investi-
gation, and portfolio priority leads to varying lev-
els of resource allocation among projects. The chal-
lenge is to identify and separate sources of inten-
tional variation from those undesirable, such as
irreproducible results and inconsistent project plan-
ning. 
Assumption 2: The process, not the people, con-
tributes predominately to the quality and perform-
ance.Because the work is defined and executed by
a team of experts in R&D, “people are the process.”
While a large amount of work in R&D is routine
and can be organized and managed as a process,
significant progress and innovation come from peo-
ple working together as a self-organizing team.
People familiar with team dynamics understand
the challenge of working with cross-functional,
multi-cultural, and multi-regional teams. Team
leaders and senior management need to under-
stand the factors that build an effective team, e.g.
commitment to goals, clear roles and responsibil-
ities, established trust and agreed collaborative
processes. In addition, multiple teams are involved
along the process from early discovery to commer-
cialization, and ownership continuity and knowl-
edge transfer are largely facilitated by people. Select-
ing the right teams and enabling them to effec-
tively bring out innovation is not a process issue –
it requires proper organization design, effective
governance, a supportive culture, individual and
team accountability, and continued development
of people. An overemphasis on process can limit
our ability to see broader issues and opportunities
that related to the organization, people and cul-
ture, and therefore not engaging the right stake-
holders, e.g. senior leadership.
In the hypothetical example above, the team
failed to understand the sources of the variability
in R&D, and approached the problem as if all
observed variation was the characteristics of the
process, i.e. “common cause” variation. In reality,
the largest contributor is “special cause” variation,
e.g. decisions and circumstances that are unique
to individual programs and teams. Furthermore,
the team treated the process as a manufacturing
or transactional process and failed to recognize
there was a large governance component in the
long cycle time. 
If a traditional process-focused improvement
effort was not enough, how could they have done
it differently?
First, there are a few concepts that are funda-
mental to our understanding of pharmaceutical
R&D productivity.
1. R&D is largely knowledge work in which a con-
siderable number of tasks cannot be well
defined. Peter Drucker raised “knowledge-work-
er productivity” as a management challenge in
the 21st century and laid out the six major fac-
tors that differentiate knowledge-worker from
manual-worker productivity (Drucker, 1999).
Traditional process-focused improvement meth-
ods were developed primarily for manual work
and have a basic assumption: most if not all
tasks can be pre-defined in a process in order
to produce the desired outcome. Consequent-
ly, we expect the process to vary within a defin-
able range. In other words, it should be stable.
To improve manual-worker productivity, the
question is about “how.” This is true in manu-
facturing or services. However, in knowledge
work, such as in R&D, the crucial question is
about “what” because all tasks are not known
in advance. A substantial amount of tasks are
progressively planned, defined and executed by
the knowledge workers themselves (individu-
ally or in collaboration). It is important to appre-
ciate the emergent nature of R&D, in which new
scientific and market information continues to
emerge and modify the subsequent activities. 
2. A process has to be purposely designed - “fit
for use.” A process in R&D should enable knowl-
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edge work productivity, e.g. enabling close col-
laboration and effective communication. The
resistance against “processes” in R&D often
comes from the perception that a process lim-
its intellectual freedom.  When designing or
changing a process in R&D, we have to strike a
careful balance between implementing best
practices and encouraging creativity. Choosing
the right processes to improve and designing
to the right level of details become critical.
3. Governance and work processes jointly con-
tribute to R&D productivity. Governance process-
es determine what is done, and work process-
es describe how things are done. A governance
process helps management establish priorities
and make critical decisions regarding project
portfolio and resources allocation in order to
achieve optimal results. A work process repre-
sents how resources (human and non-human)
are organized, based on the current knowledge
and practices, to produce a pre-specified out-
come. While the work processes are typical tar-
gets for improvement by OpEx practitioners,
the governance processes are often the bottle-
necks in R&D productivity. A different approach
is required to address governance processes.
Back to our example, the team could separate
the governance layer of the overall process from
the operational layer, and analyze them different-
ly. Much of observed cycle time variation was like-
ly due to portfolio and resource decisions, i.e. how
many projects in the portfolio and how many
resources allocated to each project, made by the
executives or governance body (see Figure 2). It
would be a waste of time trying to understand why
low priority projects with fewer resources took
longer to complete – the time-resources relation-
ship was known when the resource decision was
made. These decisions do not change the opera-
tional level detail of the work, i.e. the work process.
To reduce the overall cycle time, the management
could follow Little’s law, which states that the aver-
age cycle time is proportional to the number of
items in the process (“work-in-progress” or WIP)
and inversely proportional to the throughput. In
the case of pharmaceutical product development
process, any project, whether it is active, pending,
on-hold or even discontinued, is a WIP item as long
as it consumes organizational resources. It is com-
mon that projects in the portfolio stop moving
while the teams wait for management decisions
on resources or directions. Therefore, the obvious
improvement opportunities at the governance level
include 1) reduce the number of projects in the port-
folio and 2) simplify decision making along the crit-
ical path to allow continuous flow. The former
requires disciplined portfolio management, and
the latter requires the management to see them-
selves as servant leaders, not as authorities.  
Second, the team could use the approach for
managing special cause variation, i.e. identify and
understand outliers. At the core of Operational
Excellence is identification and separation of sources
of variation. This is true and applicable in pharma-
ceutical R&D. But the sources in pharmaceutical
R&D are much less obvious than in manufactur-
ing or services. Instead of looking for a “process”
baseline (i.e. average cycle time of the process), it
would be more productive to investigate if a “pro-
ject” baseline (i.e. the initial project plan) was cre-
ated for each project.  They could estimate the
amount of variation among project baselines that
reflected intentional or assignable variation, i.e.
their portfolio priority and scientific rationale. The
remaining variation could be attributed to two
sources: 1) process inconsistency and 2) deviations
in project execution. If of a significant size, each
source would be opportunities for focused improve-
ment with traditional OpEx tools and methods. By
developing greater appreciation of the nature of
knowledge-based work and the roles of governance
and work processes in pharmaceutical R&D, we can
start to see new opportunities beyond the process. 
Figure 2 Governance and work processes contribute to cycle time.
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4 An Opportunity: Process and Project
Management
Operational Excellence is more than a set of
tools. It is a culture of continuous improvement
that requires commitment and engagement at all
levels across the organization. In manufacturing
and services where processes are more defined,
process management (with its roots in the PDCA
cycle) has proven to be an effective mechanism to
engage the right stakeholders in continuous
improvement. Given the unique nature of pharma-
ceutical R&D, how can OpEx practitioners use
process management effectively? 
In pharmaceutical R&D, many activities change
due to unique requirements of the projects or rapid
advancement of knowledge and technology. There-
fore, activities are more project- than process-driv-
en. By Project Management Institute definition, a
project is “a temporary endeavor undertaken to
create a unique product, service, or result.” (PMI,
2013) Most of the pharmaceutical R&D activities
fit this definition. Process management is useful
only to the extent the activities are repeated, where-
as project management capabilities are specifical-
ly developed to address the unique nature of a proj-
ect.
Project management has evolved as a discipline
in the past decade. As it becomes an essential part
of product development and technology imple-
mentation in many industries, it has incorporated
a wide range of management best practices, includ-
ing Operational Excellence concepts and tools.
Unfortunately, in most organizations inexperienced
staff performs project management work. Too often,
management and staff equate project manage-
ment to “Gantt chart” management, i.e. creating
and updating project schedules on a Gantt chart.
Instead of proactively and methodically managing
various aspects of a project, these project managers
take orders from management, record meeting
minutes, update the Gantt charts, and track down
late tasks. In our view, project management goes
beyond the standard scope, time, and cost man-
agement. It systematically integrates these aspects
with quality, risk, communications, procurement,
and stakeholder management required in a proj-
ect lifecycle (PMI, 2013). The principle of progres-
sive elaboration is particularly applicable to the
emergent nature of R&D, and its emphasis on iter-
ative planning and lessons learned is consistent
with the PDCA cycle in Operational Excellence. 
One advantage of strengthening project man-
agement is that its implementation immediately
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Figure 3 Combining process and project management for continuous improvement.
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benefits the current business. Another advantage
is its real-time monitoring of project metrics, such
as deviations from the plan using earned value,
which can be leading indicators of process perform-
ance. In addition, there is a growing acceptance of
project management in the pharmaceutical R&D
organizations as scientists as well as management
recognize its benefits. Therefore, there exists a great
opportunity for OpEx practitioners working in this
industry to leverage this body of knowledge and
organizational capability for improvement. 
As a first step, OpEx practitioners have to see
the problems from both project and process per-
spectives. Process management and project man-
agement can be combined to different degrees
depending on the variability of the process and
organization’s process management maturity (see
Figure 3). For example, in a typical high-volume
manufacturer where low process variability is
desired, process management is most critical in the
pursuit of continuous improvement. As process
management is developed and matured, process
variability goes down and quality and productivi-
ty go up. In the case of pharmaceutical R&D, the
discovery phases have less defined processes than
early and late development phases. Therefore,
process management has been limited to routine
activities or at a high level in discovery, but adapt-
ed more broadly in late development processes.
Research and development activities in all phases
heavily depend on project management. So
improvement in project management capabilities
will have the biggest impact on R&D productivity.
To determine the best improvement approach,
it is helpful to assess the organizational maturity
in two dimensions: process management and proj-
ect management, as illustrated at high level in Fig-
ure 4. For example, a R&D organization with high
project management maturity but low process
management maturity may be able to execute proj-
ects successfully but only with highly experienced
project managers and teams. The capability is not
readily scalable if the demand rises because the
best practices have not been institutionalized in
the form of processes. In contrast, an organization
with high process maturity and low project man-
agement maturity may be efficient delivering stan-
dard or routine results. But if the external circum-
stances demand different outcomes, the organi-
zation may not have the right leaders and culture
Improving R&D productivity requires a balanced approach
Figure 4 Process and project management maturity assessment.
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to respond quickly. OpEx practitioners and senior
management should use this maturity assessment
with their business strategy to determine the desired
future state for the organization, and then identi-
fy the optimal path (see Figure 5).
Based on our experience, there is a greater organ-
ization capability in project management than
process management in pharmaceutical R&D. In
such a case, the organization’s project manage-
ment capability should be leveraged by OpEx prac-
titioners, i.e. project management can be a tempo-
rary substitute for process management, provid-
ing an alternative path to improved business results
until the organization becomes ready to embrace
full process management. The same maturity
assessment can also help other R&D organizations,
such as those in the medical device industry, where
both process and project management have a medi-
um level of maturity. OpEx practitioners improv-
ing R&D processes should consider the following
steps. 
1. Assess organizational maturity in process man-
agement and project management
2. Understand what is common among R&D
projects and what is unique
3. According to the organizational maturity, ap-
ply process management to standardize the
common tasks as processes, and apply project
management to manage unique tasks in proj-
ects, respectively
4. Build project plans based on governance deci-
sions, standardized work processes, and expert-
ise of the teams
5. In real time, use lessons learned during proj-
ect execution as feedback to continuously
improve existing processes
6. Continue to improve process and project
management capabilities in the organization
Figure 6 shows how governance, project man-
agement, and process management work togeth-
er to ensure project success and continuous
improvement.
Figure 5 Tailored approach based on process and project maturity.
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5 Conclusion
In summary, improving pharmaceutical R&D
using classical process-focused approaches are
unlikely to succeed without adaptation to its unique
environment. The emergent nature of R&D and
knowledge-based work mean that R&D processes
are less defined and highly variable. Governance,
organizational structure and capability have sig-
nificant impact on R&D productivity. Operational
Excellence practitioners using the traditional
approach need to look beyond the process and
question long-held assumptions. One opportuni-
ty to overcome some of these challenges is to inte-
grate project management with the Operational
Excellence methods that do apply. By carefully bal-
ancing project management and process manage-
ment in our approach to R&D productivity, we can
continually reduce variation over the long term
while improving business results from on-going
R&D projects. The effectiveness of this approach
will impact not only R&D productivity but also cul-
ture change required for continuous improvement
by embedding the PDCA mindset in everyday activ-
ities at all levels of the organization.
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